Patents by Inventor Susan KORENCHUK

Susan KORENCHUK has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230094076
    Abstract: In one embodiment, the present invention provides a combination of a Type I protein arginine methyltransferase (Type I PRMT) inhibitor and an immuno-modulatory agent selected from: an anti-PD-1 antibody or antigen binding fragment thereof, an anti-PDL1 antibody or antigen binding fragment thereof, and anti-OX40 antibody or antigen binding fragment thereof. In another embodiment, the present invention provides a pharmaceutical composition comprising a therapeutically effective amount of a Type I protein arginine methyltransferase (Type I PRMT) inhibitor and a second pharmaceutical composition comprising a therapeutically effective amount of an immuno-modulatory agent selected from: anti-PD-1 antibody or antigen binding fragment thereof, an anti-PDL1 antibody or antigen binding fragment thereof, and an anti-OX40 antibody or antigen binding fragment thereof.
    Type: Application
    Filed: September 16, 2022
    Publication date: March 30, 2023
    Inventors: Olena I. BARBASH, Andy FEDORIW, Susan KORENCHUK, Helai MOHAMMAD, Christian SHERK
  • Publication number: 20210267973
    Abstract: In one aspect, the present invention provides a method of treating cancer in a human in need thereof, the method comprising administering to the human a therapeutically effective amount of a Type II protein arginine methyltransferase (Type II PRMT) inhibitor and administering to the human a therapeutically effective amount of an ICOS binding protein or antigen binding portion thereof. In another aspect, the present invention provides a Type II protein arginine methyltransferase (Type II PRMT) inhibitor and an ICOS binding protein or antigen binding fragment thereof for use in treating cancer in a human in need thereof.
    Type: Application
    Filed: May 24, 2019
    Publication date: September 2, 2021
    Inventors: Olena I. BARBASH, Andrew Mark FEDORIW, Susan KORENCHUK, Christian S. SHERK
  • Publication number: 20210260033
    Abstract: The present disclosure provides a method of treating cancer in a human in need thereof, the method comprising administering to the human a therapeutically effective amount of a Type I protein arginine methyltransferase (Type I PRMT) inhibitor and administering to the human a therapeutically effective amount of an ICOS (CD278), Inducible T-cell Costimulator) binding protein or antigen binding portion thereof.
    Type: Application
    Filed: May 24, 2019
    Publication date: August 26, 2021
    Inventors: Andrew Mark FEDORIW, Susan KORENCHUK, Helai MOHAMMAD, Christian S. SHERK
  • Publication number: 20190350931
    Abstract: The present invention provides a combination of a Type II protein arginine methyltransferase (Type II PRMT) inhibitor and immuno-modulatory agent, wherein the immuno-modulatory agent is an anti-OX40 antibody or antigen binding fragment thereof. The present invention also provides methods for treating cancer in a human in need thereof, the methods comprising administering to the human a combination of a Type II PRMT inhibitor and an immuno-modulatory agent, wherein the immuno-modulatory agent is an anti-OX40 antibody or antigen binding fragment thereof, together with at least one of a pharmaceutically acceptable carrier and a pharmaceutically acceptable diluent, thereby treating the cancer in the human.
    Type: Application
    Filed: November 30, 2017
    Publication date: November 21, 2019
    Inventors: Olena I. BARBASH, Susan KORENCHUK, Christian SHERK
  • Publication number: 20190343803
    Abstract: In one embodiment, the present invention provides a combination of a Type I protein arginine methyltransferase (Type I PRMT) inhibitor and an immuno-modulatory agent selected from: an anti-PD-1 antibody or antigen binding fragment thereof, an anti-PDL1 antibody or antigen binding fragment thereof, and an anti-OX40 antibody or antigen binding fragment thereof. In another embodiment, the present invention provides a pharmaceutical composition comprising a therapeutically effective amount of a Type I protein arginine methyltransferase (Type I PRMT) inhibitor and a second pharmaceutical composition comprising a therapeutically effective amount of an immuno-modulatory agent selected from: an anti-PD-1 antibody or antigen binding fragment thereof, an anti-PDL1 antibody or antigen binding fragment thereof, and an anti-OX40 antibody or antigen binding fragment thereof.
    Type: Application
    Filed: November 30, 2017
    Publication date: November 14, 2019
    Inventors: Olena I. BARBASH, Andy FEDORIW, Susan KORENCHUK, Helai MOHAMMAD, Christian SHERK